Published in Clin Pharmacol Ther on March 01, 1995
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
The scientific foundation for tobacco harm reduction, 2006-2011. Harm Reduct J (2011) 1.57
Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl) (2010) 1.28
Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tob Control (2006) 1.15
Treating tobacco dependence in a medical setting. CA Cancer J Clin (2009) 1.08
A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler. Tob Control (2005) 0.99
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol (2010) 0.89
A review of smoking cessation interventions. MedGenMed (2005) 0.78
Nicotine delivery to rats via lung alveolar region-targeted aerosol technology produces blood pharmacokinetics resembling human smoking. Nicotine Tob Res (2012) 0.76
Tobacco Use Cessation and Prevention - A Review. J Clin Diagn Res (2016) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci U S A (1986) 5.59
Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 2.31
Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology (1999) 1.78
PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med (2000) 1.72
Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control (1997) 1.68
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Regional cerebral blood flow and oxygen metabolism during migraine with and without aura. Cephalalgia (1997) 1.61
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry (2001) 1.52
Ammonia, a selective agent for methane production by syntrophic acetate oxidation at mesophilic temperature. Water Sci Technol (2008) 1.52
Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging (2000) 1.49
Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem (2004) 1.47
Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord (1997) 1.42
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
[More accurate diagnosis could identify patients suitable for tacrine therapy]. Lakartidningen (1996) 1.37
Identification of human brain loci processing esophageal sensation using positron emission tomography. Gastroenterology (1997) 1.31
A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J Immunol (1986) 1.30
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology (2002) 1.30
Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology (1995) 1.26
No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol (1997) 1.25
High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res (2010) 1.23
Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem (2000) 1.23
Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry (1999) 1.21
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat (2001) 1.20
Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med (1987) 1.20
Simultaneous intracerebral microdialysis and positron emission tomography in the detection of ischemia in patients with subarachnoid hemorrhage. J Cereb Blood Flow Metab (1996) 1.18
Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res (1993) 1.17
In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta. J Immunol (1987) 1.16
Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect (1993) 1.15
The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet (2001) 1.15
Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol (1995) 1.12
Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect (1992) 1.11
Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging (2006) 1.11
Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol (2000) 1.11
Middle cerebral artery occlusion and reperfusion in primates monitored by microdialysis and sequential positron emission tomography. Stroke (2001) 1.10
Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord (2000) 1.10
Functional neuroanatomical correlates of electrodermal activity: a positron emission tomographic study. Psychophysiology (1998) 1.09
Brain activation in young and older adults during implicit and explicit retrieval. J Cogn Neurosci (1997) 1.09
Pharmacokinetics of nicotine in healthy elderly people. Clin Pharmacol Ther (2001) 1.08
Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl) (1993) 1.08
Postnatal changes of nicotinic acetylcholine receptor alpha 2, alpha 3, alpha 4, alpha 7 and beta 2 subunits genes expression in rat brain. Int J Dev Neurosci (1998) 1.07
Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med (2014) 1.07
The preparation of 11C-methyl iodide and its use in the synthesis of 11C-methyl-L-methionine. Int J Appl Radiat Isot (1976) 1.06
Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res (1999) 1.06
D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol (2001) 1.05
Safety of lumbar puncture procedures in patients with Alzheimer's disease. Curr Alzheimer Res (2009) 1.05
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord (2010) 1.04
Studies of signal suppression in liquid chromatography-electrospray ionization mass spectrometry using volatile ion-pairing reagents. J Chromatogr A (2001) 1.03
Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett (1986) 1.03
Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun (2007) 1.03
PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med (1991) 1.03
Manganese induced brain lesions in Macaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging. Arch Toxicol (1992) 1.02
Haemodynamic and metabolic disturbances in the acute stage of subarachnoid haemorrhage demonstrated by PET. Acta Neurol Scand (2004) 1.02
Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol (1999) 1.02
A monoclonal antibody to the IL-1 beta peptide 163-171 blocks adjuvanticity but not pyrogenicity of IL-1 beta in vivo. J Immunol (1989) 1.02
Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res Dev Brain Res (1998) 1.02
Non-synchronous behavior of neuronal activity, oxidative metabolism and blood supply during mental tasks in man. Neurosci Lett (1994) 1.02
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem (2004) 1.02
Muscarinic receptors in human SH-SY5Y neuroblastoma cell line: regulation by phorbol ester and retinoic acid-induced differentiation. Brain Res (1987) 1.01
Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress. Neurobiol Dis (2007) 1.01
Principal component analysis of dynamic positron emission tomography images. Eur J Nucl Med (1994) 1.01
Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr (1983) 1.00
Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology (1996) 1.00
Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease. Eur J Clin Pharmacol (1982) 0.99
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol (2005) 0.99
[Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)]. Arch Pediatr (2005) 0.99
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm (Vienna) (2006) 0.99
Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res (2000) 0.98
Bacterial aerosols in dental practice - a potential hospital infection problem? J Hosp Infect (2006) 0.98
Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol (1996) 0.98
Somatotopic organization along the central sulcus, for pain localization in humans, as revealed by positron emission tomography. Exp Brain Res (1997) 0.97
Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. Neurobiol Dis (2004) 0.96
Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging (2005) 0.96
Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab (2005) 0.96
PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. J Nucl Med (1996) 0.96
Synthesis of alpha beta-poly((2-hydroxyethyl)-DL-aspartamide), a new plasma expander. J Med Chem (1973) 0.94
Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet (1996) 0.94
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord (2001) 0.94
HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun (2007) 0.94
A metabolic threshold of irreversible ischemia demonstrated by PET in a middle cerebral artery occlusion-reperfusion primate model. Acta Neurol Scand (2000) 0.94
Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett (1994) 0.94
Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm (Vienna) (1997) 0.94
A novel bronchodilator xanthine apparently without adenosine receptor antagonism and tremorogenic effect. Eur J Respir Dis (1983) 0.94
Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.94
[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat Disord (2007) 0.93
Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization. Brain Res (1989) 0.93
Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol (1998) 0.93
Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. Neuropharmacology (2000) 0.93
Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol (1999) 0.92
Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine. Clin Pharmacol Ther (1996) 0.92
Possible effects of tetrahydrobiopterin treatment in six children with autism--clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol (1997) 0.92
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm (Vienna) (2005) 0.91